pacific – PressAP

JCN Newswire

Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region

January 26, 2023

TOKYO, Jan 26, 2023 - (JCN Newswire via SEAPRWire.com) - Nippon Steel Corporation, Mitsubishi Corporation and ExxonMobil Asia Pacific Pte. Ltd. have signed a Memorandum of Understanding to jointly study carbon capture and storage (CCS) and the establishment of potential CCS value chains in the Asia Pacific regions on January 25, 2023. Based on the Memorandum, the three companies will conduct research on the capture of CO2 emissions from Nippon Steel's domestic steelworks and evaluate the necessary infrastructure development required, with a view to establishing CCS value chains in the Asia-Pacific region. It would also include a detailed evaluation of Asia Pacific storage opportunities, including in Malaysia, Indonesia and Australia. Mitsubishi Corporation plans to evaluate the overseas CO2 transportation and the development of CCS value chain. This is the first study to develop value chains for carbon capture in Japan with the aim to store elsewhere overseas in the region. Nippon Steel set forth the "Nippon Steel Carbon Neutral Vision 2050" in its medium- to long-term management plan announced in March 2021 and positioned CCS as one of the key technologies to realize this vision. Through this study, Nippon Steel will progress the implementation of CCS including securing storage sites for overseas storage of CO2 generated from steel works, developing storage infrastructure, advocating for policies and regulation, and examining its cost adequacy. Mitsubishi Corporation has identified Energy Transformation (EX) as a key initiative in its Roadmap for a Carbon Neutral Society formulated in October 2021 and its Medium-Term Management Strategy 2024 released in May last year. Mitsubishi Corporation will evaluate the overseas CO2 transportation and the development of CCS value chain through this joint effort. ExxonMobil continues to advance innovative solutions for a lower-carbon future. In early 2021, it established a Low Carbon Solutions business, which is working to bring lower-emission technologies to market, making them accessible to hard-to-decarbonize industries. It is committed to accelerating significant emission reductions through strategic collaborations and through leading the development and the deployment of scalable lower-emission technologies, such as CCS, needed to advance solutions for various industries in the Asia Pacific region and beyond. Mitsubishi Corporation will continue to lead EX through the low-carbon and decarbonization of our business through CCS and other initiatives, while contributing to the transition and realization of a carbon-neutral society through the stable supply of cleaner energy. About Nippon Steel CorporationNippon Steel Corporation is Japan's largest and one of the world's leading integrated steel producers with a wide range of value-added steel products in more than 15 countries. Nippon Steel has four business segments: steelmaking and steel fabrication, engineering and construction, chemicals and materials, and system solutions. With the aim of continually growing to become "the best steelmaker with world-leading capabilities" from the present and into the future, Nippon Steel will pursue world-leading technologies and manufacturing capabilities, and contribute to society by providing excellent products and services. For more information about Nippon Steel please visit: www.nipponsteel.com/ About Mitsubishi CorporationMitsubishi Corporation works with its roughly 1,700 subsidiaries, affiliates and group companies to develop businesses in approximately 90 countries around the world. Spanning multiple industries and regions, these businesses are overseen by Mitsubishi Corporation's Industry DX Group and 10 Business Groups: Natural Gas, Industrial Materials, Petroleum & Chemicals, Mineral Resources, Industrial Infrastructure, Automotive & Mobility, Food Industry, Consumer Industry, Power Solution, and Urban Development. Through joint digital (DX) and energy (EX) transformations invested in sustainability, decarbonization and digitalization, the company is now focused on leveraging its operations to address myriad challenges that stand to impact our planet's future. About ExxonMobilExxonMobil, one of the largest publicly traded international energy and petrochemical companies, creates solutions that improve quality of life and meet society's evolving needs. The corporation's primary businesses - Upstream, Product Solutions and Low Carbon Solutions - provide products that enable modern life, including energy, chemicals, lubricants, and lower-emissions technologies. ExxonMobil holds an industry-leading portfolio of resources, and is one of the largest integrated fuels, lubricants and chemical companies in the world.The Singapore affiliate, ExxonMobil Asia Pacific Pte. Ltd., has manufacturing facilities which include an integrated world-scale refining and petrochemical complex in Jurong and Jurong Island. Our operations and businesses serve customers and commercial markets in the region with ground transportation, industrial, aviation and marine fuels, lubricants, petrochemicals and liquefied natural gas. To learn more, visit exxonmobil.com and the Energy Factor. Follow us on Twitter and LinkedIn. For further information, contact:Nippon Steel Corporation, Public Relations Center Tel: 03-6867-2977Mitsubishi Corporation, Press Relations Team, Corporate Communications Dept. Tel: 03-3210-2171 Fax: 03-5252-7705ExxonMobil Asia Pacific Pte. Ltd: +65 6885 2389 Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Novotech is Gold Sponsor at Biotech Showcase 2023

December 20, 2022

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.Meetings can be scheduled via the PartneringOne portal. https://informaconnect.com/biotech-showcase/partnering/Novotech will share the Asia Pacific advantages for expedited clinical trials, where biotechs have access to Novotech's vast patient populations, strong local regulatory knowledge, extensive site and KOL networks, and reputation for data quality.Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific. According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

Olympus Named to Dow Jones Sustainability World Index for Two Consecutive Years

December 16, 2022

TOKYO, Dec 16, 2022 - (JCN Newswire via SEAPRWire.com) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, announced that it has been selected for inclusion in the 2022 Dow Jones Sustainability World Index (DJSI World) and the 2022 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), both among the most globally recognized corporate sustainability indices. Olympus has been named to the DJSI World for two consecutive years and DJSI Asia Pacific for four.The Dow Jones Sustainability Indices (DJSI) are corporate sustainability evaluation indices for environmental, social, and governance (ESG) investment. Jointly developed by S&P Dow Jones Indices and RobecoSAM, the DJSI track the financial performances of leading companies according to ESG criteria. These indices are updated annually to include companies with excellent corporate sustainability practices.In 2022, 332 companies were selected as DJSI World members from approximately 3,500 companies worldwide in 61 industry sectors, and 156 companies were selected as DJSI Asia Pacific members from approximately 600 companies assessed in the region. Olympus is one of only 8 out of 64 companies to have been included in the DJSI World Health Care Equipment & Supplies sector. The company's scores on Access to Healthcare, Talent Attraction & Retention, Tax Strategy, Environmental Policy & Management Systems were of particular note, being not only highly rated, but having also been improved over last year's scores. In addition to the DJSI World and Asia Pacific, Olympus was also named to the FTSE4Good Index Series and FTSE Blossom Japan Index.Stefan Kaufmann; Director, Executive Officer, and Chief Administrative Officer of Olympus, stated: "It is a great honor for Olympus to again be selected for the DJSI World and Asia Pacific. In order to realize Our Purpose of Making people's lives healthier, safer and more fulfilling, we have taken various initiatives to contribute to society, positioning ESG as one of the most important strategic pillars in our Corporate Strategy. We are proud to be included in the DJSI World and Asia Pacific for consecutive years as evidence of our continuous evolution as well as our high reputation in ESG from stakeholders. We will further accelerate our efforts to realize a sustainable society."Based on Our Purpose, Olympus believes that the sustainability of a company will be recognized primarily by meeting the demands and expectations of society and fulfilling responsibilities through dialogue with all stakeholders. The company will continue to contribute to creating a sustainable society by actively engaging in activities that incorporate ESG perspectives to fulfill its corporate social responsibilities on a global scale.For more information on Olympus' ESG initiatives, please refer to its Integrated Report 2022[1] and the Sustainability page on its website[2].[1] https://www.olympus-global.com/ir/data/integratedreport/2022.html?page=ir[2] https://www.olympus-global.com/csr/About OlympusOlympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp ( https://twitter.com/olympus_corp ).Media contact:Mieko YamadaGlobal-Public_Relations@olympus.comOlympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS] https://www.olympus-global.com Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Data Shows 50% of New Trials Have Sites in Asia Pacific

December 15, 2022

SYDNEY, AU, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. In addition, analysis of trial growth trends found that Asia Pacific has also seen high phase-level growth over the 5-year analysis period to 2022.- Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.- US and EU remained stable at approximately 20% at phases I through III.- RoW representation is low in phases I and II but on par with the US and EU in phase III.Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006. Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities. Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience. "Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

December 6, 2022

SYDNEY, AU, Dec 6, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience."Every day our team supports biotech companies in their drug development programs with unparalleled regulatory knowledge, vast site and investigator networks, technology-driven clinical data management, and a project management approach focused on problem-solving, ownership, and flexibility. Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech Novotech is the leading Asia Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Asian and Pacific Countries Adopt Jakarta Declaration 2023-2032

October 24, 2022

JAKARTA, Oct 24, 2022 - (ACN Newswire via SEAPRWire.com) - The 'High-level Intergovernmental Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities' (HLIGM APDPD) closed on Friday (Oct 21) with 53 Asia-Pacific and 9 associated countries adopting the landmark Jakarta Declaration, marking the start of the fourth 'Asian and Pacific Decade of Persons with Disabilities'.53 Asia-Pacific and 9 associated UN ESCAP countries adopted the Jakarta Declaration 2023-2032, October 21, 2022. (ANTARA/Ministry of Social Affairs)Participants in the Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities 2013-2023, Oct 21, 2022. (ANTARA/Ministry of Social Affairs)"Today, on the last day of the high-level intragovernmental meeting in the Asia Pacific, we are adopting the Jakarta Declaration 2023-2032, which will be followed up by all members, accelerated and implemented," said the meeting chair and Indonesian Social Affairs Minister, Tri Rismaharini (Risma). "Through the Jakarta Declaration, we reaffirm our global commitment to a better life for all persons with disabilities," said Risma, emphasizing the commitment of Asia Pacific countries in realizing the Incheon Strategy, initiated ten years ago. "The priority issue is an alignment of the Convention on the Rights of Persons with Disabilities (CRPD) at the level of legislation.""It is time to increase efforts and take affirmative steps to implement universal design in all public areas, to increase the capacity of people handling persons living with disabilities in all sectors, and conduct national breakthrough campaigns to build awareness about disability," she said. "Harmonization of legislation is the toughest challenge for our own government, as it has central, provincial and regency/city government levels."Under-Secretary-General of the United Nations, and Executive Secretary of the Economic and Social Commission for Asia and the Pacific (UN ESCAP), Armida Salsiah Alisjahbana said although the implementation of the CRPD was making progress, people with disabilities in the Asia Pacific region face obstacles in education, work, decision making, and many other aspects.She invites UN ESCAP members to strengthen partnerships with disability organizations, the private sector, United Nations entities and the others to create a comprehensive community approach. Armida hopes that people with disabilities can participate in all policies and programs related to disability actively and significantly, in line with the spirit of 'nothing without us about us'.HLIGM APDPD was held on a hybrid basis from 19 - 21 October 2022 and was attended by delegates from 53 member states, 9 association member, observer countries, UN agencies, and civil society organizations.Written by: PR Wire, Editor: PR Wire (c) ANTARA 2022Source article at: https://en.antaranews.com/news/256377/asia-and-pacific-countries-make-jakarta-declaration-agreementUN ESCAP member countries also underlined the importance of making strategic investments to push disability-inclusive development through a whole-society approach in collaboration with relevant stakeholders, especially organizations of persons with disabilities and private sector entities, in order to accelerate action to promote and protect the rights of persons living with disabilities."I encourage all participants to continue their cooperation with one another and to take all necessary steps to make the recommendations formulated during this meeting in Jakarta. Now and in the next decade, we must come together and work it out," Rismaharini said.The first point of the Jakarta Declaration is to harmonize national legislations with the Convention on the Rights of Persons with Disabilities, after the convention is ratified, by conducting a comprehensive and regular review of national legislations and appropriate regional regulations.The second is to promote the meaningful participation of women and men with disabilities of all ages, including by closely consulting and actively involving children and youth with disabilities through their representative organizations, in planning, implementation, and decision-making on policies, programs, and political processes through reasonable accommodation.The third point involves special attention to the special needs of persons with diverse disabilities and women, children, and elderly with disabilities to increase accessibility of the physical environment, including information and communication technology and systems, public transportation, and essential information and services related to disaster risk and public health emergencies and other public services.The fourth is to promote the power of the private sector, including its resources, innovation, and technology talent, to push disability-inclusive development by adopting disability-inclusive public procurement policies to promote the adoption of universal design and accessibility measures for infrastructure, technology, and information and communication services that are publicly obtained.The fifth is to promote a gender-responsive life cycle approach to develop and implement policies and programs related to disability by paying special attention to children, youth, women, and elderly people living with disabilities.The sixth is to take action, based on information provided by competent national institutions and other recognized sources, to close the disability data gap and strengthen the capacity to track progress in disability-inclusive development at the national and subnational levels by producing comparable and qualified data as chosen by gender, age, and disability across sectors. Written by: Devi Nindy Sari R, Resinta S, Editor: Rahmad Nasution (c) ANTARA 2022Source article: https://en.antaranews.com/news/256205/53-asia-pacific-countries-agree-to-jakarta-declaration-on-disability Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Asia and Pacific countries make Jakarta Declaration agreement

October 23, 2022

JAKARTA, Oct 23, 2022 - (ACN Newswire via SEAPRWire.com) - The High-level Intergovermental Meeting on The Final Review of The Asian and Pacific Decade of Persons with Disabilities (HLIGM APDPD) was closed with the Jakarta Declaration agreement, which marked the start of the fourth decade of Asia and Pacific Decade of Persons with Disabilities.Participants of the meeting on the final Review of the Asian and Pasific Decade of Persons with Disabilities 2013-2023 in Jakarta, Friday (October 21, 2022).(ANTARA/Ministry of Social Affairs)"Today is the last day and the high-level meeting between governments in the Asia Pacific was closed and we are making the Jakarta Declaration 2023-2032 which will be followed up by members, accelerated and implemented," said Indonesian Social Affairs Minister Tri Rismaharini in Jakarta.The Jakarta Declaration is expected to be able to reaffirm the commitment of the governments of Asia Pacific countries in realizing the Incheon Strategy, which was initiated ten years ago.The Jakarta Declaration has six resolutions. One of the priority issues is the alignment of the Convention on the Rights of Persons with Disabilities (CRPD) at the level of legislation.According to Risma, harmonization of legislation is the toughest challenge for the Indonesian government because it has three levels of government, namely, the central government, provincial government and regency/city government.Meanwhile, Under-Secretary-General United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Armida Salsiah Alisjahbana, said although the implementation of the CRPD making progress, people with disabilities in the Asia Pacific region face obstacles in education, work, decision making, and many other aspects.Therefore he invites UNESCAP members to strengthen new partnerships with disability organizations, the private sector, United Nations entities and the others to create a comprehensive community approach.Armida hopes that people with disabilities can participate in all policies and programs related to disability actively and significantly, in line with the spirit of 'nothing without us about us'.HLIGM APDPD was held on a hybrid basis during 19 - 21 October 2022 and was attended by delegates from 53 member states, 9 association member, observer countries, UN agencies, and civil society organizations.See the original article: https://en.antaranews.com/news/256377/Written by: PR Wire, Editor: PR Wire (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Alex Shead Appointed as an Independent Director of Pacific Green Technologies, Inc.

October 19, 2022

DOVER, DE, Oct 19, 2022 - (ACN Newswire via SEAPRWire.com) - Pacific Green Technologies, Inc. (the "Company" or "Pacific Green", (OTCQB:PGTK) announces that Alexander Shead has been appointed as an Independent Director, effective October 16th, 2022. Alex previously served as Executive Director for the Company from July 2016 to October 2020.Alex is Chairman of Lockton Pacific (2012-present), a subsidiary of Lockton Companies, Inc., the world's largest privately held, independent insurance brokerage firm, ranked 8th largest globally. Alex is also the Responsible Manager with the Australian Securities and Investments Commission (ASIC).In 2008, Alex conceived the award-winning Non-Governmental Organization (NGO), Food Ladder, and remains Chairman today. Food Ladder was one of the first NGOs in the world to use environmentally sustainable technologies to create food and economic security for communities affected by poverty. Alex was also the founder of Fair Repairs, a social enterprise which delivers training and employment opportunities to individuals suffering from long term unemployment and disadvantage.Alex is a British, Australian and Swiss national, educated at Harrow School in England and La Sorbonne University in Paris, France. In 1993, Alex co-founded Stuart Alexander, leading the company to become one of the UK's largest insurance and risk management advisory businesses, ultimately selling to AXA, UK.In 2004, Alex relocated to Australia where he was a shareholder and director of Milne Alexander, a boutique insurance broking and advisory firm. From 2008 to 2014, Alex was the Executive Chairman of the Mecon Winsure Insurance Group, one of Australia's leading insurance and underwriting agencies, acting as a Coverholder for Lloyd's of London and local Australian insurers. Mecon Winsure Insurance Group was sold to ASX-listed Steadfast Group Ltd. in 2014.Alex's track record of creating shareholder value through Merger and Acquisition (M&A) activity has spanned over three decades. Alex has a wide range of entrepreneurial experience and an in-depth knowledge of large-scale enterprise acquisition and operational integrations, having successfully led over 40 business transactions.About Pacific Green Technologies, Inc.Pacific Green Technologies, Inc. is focused on addressing the world's need for cleaner and more sustainable energy. The Company offers BESS, Concentrated Solar Power (CSP) and Photovoltaic (PV) energy solutions to complement its marine environmental technologies and emissions control divisions. For more information, visit Pacific Green's website: www.pacificgreentechnologies.comNotice Regarding Forward-Looking Statements:This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, any potential business developments and future interest in the Company's battery, solar and emissions control technologies.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, general economic and political conditions, and the ongoing impact of the COVID-19 pandemic. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's annual report on Form 10-K for the most recent fiscal year, the Company's quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.Contact:Scott Poulter, Chairman & CEOPacific Green TechnologiesT: +1 (302) 601-4659SOURCE: Pacific Green Technologies, Inc. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval

October 17, 2022

SYDNEY, AU, Oct 17, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval.Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss:- why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data- what actionable strategies can be implemented to leverage Asia Pacific's recruitment potential to accelerate your clinical development- how Phase 1 data from Australia is acceptable to the FDA and can be used to launch global drug development programs- deep insight into processes for designing and delivering a robust clinical program- biotech challenges and opportunities in the post-COVID environment with a focus on global investments and drug pipelinesRegister for the webinar here https://webinars.endpts.com/the-biotech-landscape-market-trends-priorities-predictions-and-pathways-to-fda-approval/October 18, 20221:00 pm - 2:00 pm EDTThe industry leaders presenting include:- Yi Larson, Chief Financial Officer of LianBio. Formerly Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, Inc., and Goldman Sachs & Co. LLC, Managing Director of Healthcare Investment Banking- Kasey Kime, Director of Regulatory Affairs for Novotech's in-house consulting group, BioDesk- Dr. Jeanne M. Novak, President and CEO of CBR International Corp., a full-service product, clinical, and regulatory strategy group- Dr. Fred Cohen, a Co-Founder and Chairman of Monograph Capital Partners. He is also a Co-Founder and Senior Managing Director at Vida Ventures.Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC

September 5, 2022

SYDNEY, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.The clinical data compiled by GlobalData for Novoteoch also found that: "By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan. In the APAC region, the proportion of oncology trials doubled during 2017-2021. In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."Download the Reports Here:IMMUNO-ONCOLOGY - ASIA PACIFIC - CLINICAL TRIAL LANDSCAPE https://novotech-cro.com/whitepapers/immuno-oncology-asia-pacific-clinical-trial-landscapeEVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Aggresive in Global Market Expansion, PIS Meets BP, Shell, and Exxon in Singapore

September 4, 2022

SINGAPORE, Sep 3, 2022 - (ACN Newswire via SEAPRWire.com) - Pertamina International Shipping (PIS) is increasingly targeting consumers in the international market. In addition to this expansion, PIS strives to continuously improve the quality and standard of service by exchanging knowledge and experiences with world energy companies.PT Pertamina International Shipping (PIS), in cooperation with PIS Pte Ltd (PIS PL), hosted a sharing session with BP Singapore Pte. Limited, Shell International Eastern Trading Co (SIETCO), and ExxonMobil Asia Pacific Pte Ltd. The meeting was held at the offices of each energy company on August 24-25, 2022, in Singapore.PIS, in cooperation with PIS Pte Ltd (PIS PL), hosted a sharing session with BP Singapore Pte. Limited, Shell International Eastern Trading Co (SIETCO), and ExxonMobil Asia Pacific Pte Ltd. The meeting was held at the offices of each energy company on August 24-25, 2022, in Singapore.During the sharing session, PIS discussed vetting, inspection, and vessel acceptance or vessel examination and inspection. The event was attended by PIS Director of Operations Arief Kurnia Risdianto, PIS PL Managing Director Brilian Perdana, Crude and Gas Operation (CGO) Vice President Harris Abdi Sembiring, and PIS Loss Prevention Safety Quality (LPSQ) Manager Soleh Komaruddin.BP Singapore Pte Ltd Vetting and Clearance Senior Manager, ExxonMobil Asia Pacific Pte Ltd Asia Pacific Supply Coordinator, ExxonMobil Asia Pacific Pte Ltd Mogas Lead, ExxonMobil Asia Pacific Pte Ltd Global Senior Marine Operations, SIETCO Mogas Operation Team Lead, SIETCO Head of Marine, SIETCO Senior Originator, and more were also in attendance at this meeting.The meeting was also a PIS endeavor to escalate acceptance of its ships at the terminals of world energy participants such as BP, Shell, and Exxon to showcase the existence and quality of PIS in international settings. In the maritime and energy sectors, these companies are significant participants that dominate the tanker chartering market called the Seven Sisters.PIS Director of Operations, Arief Kurnia Risdianto, explained PIS performance which has now explored 12 international routes. PIS ships have met international shipping standards, including the Paris MOU for sailing requirements on the European continent and a Certificate of Compliance from the United States Coast Guard (USCG)."PIS is the largest tanker operator in Southeast Asia, currently operating around 439 vessels with extensive experience serving the domestic and regional market," he said.Experience of PIS in serving the regional market is recorded by many international customers, including Vitol, Petronas, Trafigura, BP, Badak LNG, ExxonMobil, Petrobras, Chevron, Saudi Aramco, Shell, and many more.As the Integrated Marine Logistics Sub Holding of PT Pertamina (Persero), PIS business includes shipping, marine services, port services, port and jetty management (port ownership), storage tanks, and other related services.PIS owns two VLCCs, namely, Pertamina Pride and Pertamina Prime, with a capacity of 2 million barrels and incurs the Eco-Green Vessel concept. The two VLCCs are tangible manifestations of PIS endeavor to lead the marine and logistics business in both domestic and international markets.Besides oil and gas, PIS expands its business potential to various segments and cargo types, including petrochemicals with medium-range chemical-specific vessel assets called PIS Precious.In the meantime, to comply with regional trading and improve its role in the global market, Tanjung Uban offers an integrated terminal managed by the PIS subsidiary.PIS CEO Erry Widiastono said that the company has prepared a roadmap to support energy transition programs. "PIS will anticipate the future of vessels business, specifically the greener vessels. For example, vessels responsible for gas shipping such as LPG, LNG, and many others. In the future, we will anticipate the progress of the renewable energy sector," said Erry.About Pertamina International Shipping (PIS)As the Integrated Marine Logistics Sub Holding, PT Pertamina International Shipping (PIS) consistently stimulates Indonesia's economic growth through safe and sustainable operation, becomes a trusted and reliable maritime partner, and promotes value for the stakeholders in running their business. See https://pertamina-pis.com/. Media Contact:M Aryomekka FirdausCorporate SecretaryM: +62-811-872-272E: aryomekka@pertamina.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

Jurong Port, Mitsubishi Heavy Industries Asia Pacific and JERA Asia Come Together to Explore Establishing an Ammonia Direct Combustion Power Plant

August 22, 2022

Singapore, Aug 22, 2022 - (JCN Newswire via SEAPRWire.com) - Jurong Port, Mitsubishi Heavy Industries Asia Pacific (MHI-AP), a subsidiary of Mitsubishi Heavy Industries, and JERA Asia, a subsidiary of JERA, today concluded a Memorandum of Understanding (MoU) to jointly explore establishing a 100% ammonia direct combustion power plant on Jurong Island, Singapore, which houses the country's chemical and energy industries.Under the MoU, a joint study will be conducted, where a 60MW class gas turbine combined cycle plant fueled by 100% ammonia is planned to be set up to produce carbon-neutral electricity, as well as stimulate ammonia demand to be ready for ammonia bunkering in future.This MoU builds upon an initial agreement between Jurong Port and MHI-AP signed in August 2021 for a pre-feasibility study on ammonia direct combustion technology for green power generation, which was concluded successfully in March 2022.In February this year, the Singapore government raised its climate ambition to achieve net-zero CO2 emissions by or around 2050. This project is in alignment with the overall national decarbonization goals, as it aims to utilize ammonia - which can efficiently transport and store hydrogen in a liquid state at low cost - as a fuel to generate carbon-free electricity, and as the main bunkering fuel in future to decarbonize the maritime sector. The MoU will hence explore the viability and commercialization of ammonia for these purposes."We feel this MoU could help pave the way for encouraging the adoption of hydrogen in Singapore through aggregation of demand across multiple sectors, mainly the power sector and the maritime sector, thereby addressing the chicken-and-egg conundrum of infrastructure versus demand needs for maritime and domestic power generation. This collaboration is certainly consistent with the spirit of reinforcing Singapore's premier bunkering hub status - for current, transition and future fuels," said Ooi Boon Hoe, Chief Executive Officer, Jurong Port.Osamu Ono, Managing Director, MHI-AP, said: "Ammonia, which consists of hydrogen and nitrogen, is a highly efficient hydrogen carrier and can be directly combusted as a carbon neutral fuel, thereby contributing to the establishment of a robust hydrogen value chain. At MHI, we believe that ammonia and hydrogen are key fuels that can help countries meet their net zero goals, and this MoU is an exciting opportunity for us to contribute our technology and expertise to achieve sustainable development in Singapore and subsequently realize the global sustainability agenda.""JERA is committed to providing cutting edge solutions to the world's energy issues and is actively working to strengthen both the ammonia and hydrogen value chains. We believe this MoU offers a unique opportunity to support Singapore's decarbonization efforts while advancing the ammonia technology development for carbon neutral power generation. Through initiatives like this, JERA will leverage its experience and capabilities to help countries to reach their net-zero CO2 emissions targets and to build a clean energy supply chain in the region," said Toshiro Kudama, Chief Executive Officer, JERA Asia.Together, the three companies will contribute to achieving net-zero CO2 emissions in Singapore by leveraging their technology, resources and expertise.About Jurong PortJurong Port (JP) is a world-class multipurpose port operator serving as Singapore's premier gateway for general and bulk cargo. Its port operating expertise includes efficient handling of general, bulk, and containerised cargo at JP Homeport, management and operations of the Tuas Offshore Marine Centre, Lighter Terminals in Penjuru and Marina South as well as overseas ports in China and Indonesia. JP also owns and operates two of the most modern tank storage terminals in Singapore - Jurong Port Tank Terminals (JPTT) and Jurong Port Universal Terminal (JPUT). With a combined storage capacity of almost 3 million m3, JP is the largest independent storage terminal operator in Singapore. JPUT, in particular, supports approximately 30% of Singapore's annual bunkering volume, reinforcing the nation's position as the top bunkering hub in the world. JP caters to regional and domestic markets across diverse industry supply chains which include construction, shipbuilding, offshore, transport, logistics, energy, and manufacturing industries. JP's local and overseas terminals handled a total of 70 million tons of general and bulk cargo and more than half a million TEUs in 2021. Amongst others, JP won the Lloyd's List Asia Pacific Port/ Terminal Operator of the Year Award in 2018 and the National Infocomm Award for Most Innovative Use of Infocomm Technology (Private Sector) in 2016.For more information, please visit www.jp.com.sg or follow us on Facebook and Linkedin.About Mitsubishi Heavy Industries Asia Pacific (MHI-AP)Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP) is a subsidiary of Mitsubishi Heavy Industries, Ltd. (MHI), one of the world's leading industrial firms. Located in Singapore, the Asia Pacific headquarters supports the growth of markets in Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Myanmar, India, Australia and other parts of the region. MHI-AP builds on its global outlook and deep local insights to deliver integrated solutions to the region in urban development and infrastructure, energy and utilities, as well as logistics and transportation. As a market leader in Asia Pacific, MHI-AP provides reliable and innovative solutions that move the world forward.For more information, visit www.mhi.com/.About JERAEstablished in 2015, JERA is an equal joint venture of two major Japanese electric companies, TEPCO Fuel & Power Incorporated and Chubu Electric Power Company. JERA is an energy company with global reach that has strength in the entire energy supply chain, from participation in LNG upstream projects and fuel procurement, through fuel transportation to power generation. JERA's mission is to provide cutting edge solutions to the world's energy issues, by offering energy supply models established in Japan through JERA's global operations to other countries. JERA has recently established its New Corporate Vision for 2035, indicating its goal "To scale up its clean energy platform of renewables and low greenhouse gas thermal power, sparking sustainable development in Asia and around the world". With this context, JERA is interested in the development of the ammonia value chain in Singapore and the overall strategic vision towards sustainable development in Asia and around the world.For more details: https://www.jera.co.jp/english/About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)